{"version":"1.0","type":"link","title":"Redefining HER2 in Breast Cancer: From Conventional Positivity to Low and Ultralow in the New Era of Antibody-Drug Conjugates.","author_name":"Koh J 외","author_url":"https://prs-insight.online/author/Koh%20J","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/89415","thumbnail_width":1200,"thumbnail_height":630}